89665-79-2

Basic information

• Product Name: Benzenemethanesulfonamide, 2-chloro-
• Synonyms: 2-chloro-Benzenemethanesulfonamide;Benzenemethanesulfonamide, 2-chloro-;2-chlorobenzylsulfonamide;(2-Chlorophenyl)Methanesulfonamide(WX682906)
• CAS NO: 89665-79-2
• Molecular Formula: C₇H₈ClNO₂S
• Molecular Weight: 205.66
• Mol File: 89665-79-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 374°C at 760 mmHg
• Flash Point: 180°C
• Appearance: /
• Density: 1.444g/cm³
• Vapor Pressure: 8.59E-06mmHg at 25°C
• Refractive Index: 1.598
• PKA: 10.07±0.60(Predicted)
• CAS DataBase Reference: Benzenemethanesulfonamide, 2-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanesulfonamide, 2-chloro-(89665-79-2)
• EPA Substance Registry System: Benzenemethanesulfonamide, 2-chloro-(89665-79-2)

Safety Data

• Hazardous Substances Data: 89665-79-2(Hazardous Substances Data)

Usage

General Description

Benzenemethanesulfonamide, 2-chloro- is a chemical compound with the molecular formula C7H8ClNO2S. It is commonly used as a sulfa drug, which means it contains a sulfonamide group and is often used as an antibiotic to treat bacterial infections. The presence of the 2-chloro- group in the molecule indicates that it has a chlorine atom attached to the second carbon of the benzene ring. This chemical compound works by inhibiting the growth and reproduction of bacteria, making it an effective treatment for a variety of infections. However, it is important to use this compound under the guidance of a healthcare professional to ensure its proper and safe usage.

InChI:InChI=1/C7H8ClNO2S/c8-7-4-2-1-3-6(7)5-12(9,10)11/h1-4H,5H2,(H2,9,10,11)

Upstream product

• 77421-13-7 (2-chlorobenzyl)sulfonyl chloride 
• 41345-36-2 Sodium 2-chlorobenzylsulphonate 

Downstream Products

• 105971-41-3 (2-chloro-phenyl)-methanesulfonic acid-[bis-(2-cyano-ethyl)-amide] 
• 91561-44-3 3-(2-Chlor-benzylsulfonyl)-1-butyl-harnstoff 
• 111248-89-6 1,3-dihydro-2,1-benzisothiazole 2,2-dioxide 
• 24827-66-5 1-methyl-1,3-dihydrobenzo[c]isothiazole-2,2-dioxide 
• 111248-94-3 1,3-dihydro-5-nitro-2,1-benzoisothiazole 2,2-dioxide 
• 111249-11-7 (2,2-Dioxo-2,3-dihydro-2λ⁶-benzo[c]isothiazol-1-yl)-phenyl-methanone 
• 111249-13-9 1-(4-chlorobenzoyl)-1,3-dihydro-2,1-benzisothiazole 2,2-dioxide 
• 111249-12-8 (2-Chloro-phenyl)-(2,2-dioxo-2,3-dihydro-2λ⁶-benzo[c]isothiazol-1-yl)-methanone 
• 111249-10-6 1-(2,2-Dioxo-2,3-dihydro-2λ⁶-benzo[c]isothiazol-1-yl)-2-phenyl-propan-1-one 
• 111249-15-1 (5-Chloro-2,2-dioxo-2,3-dihydro-2λ⁶-benzo[c]isothiazol-1-yl)-(4-chloro-phenyl)-methanone 
• 111249-17-3 (5-Bromo-2,2-dioxo-2,3-dihydro-2λ⁶-benzo[c]isothiazol-1-yl)-(4-chloro-phenyl)-methanone 
• 111249-21-9 1-(Toluene-4-sulfonyl)-1,3-dihydro-benzo[c]isothiazole 2,2-dioxide 
• 111249-18-4 (4-Chloro-phenyl)-(5-nitro-2,2-dioxo-2,3-dihydro-2λ⁶-benzo[c]isothiazol-1-yl)-methanone 
• 111249-19-5 (4-Chloro-phenyl)-(7-nitro-2,2-dioxo-2,3-dihydro-2λ⁶-benzo[c]isothiazol-1-yl)-methanone 

Relevant articles and documents

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine series and present the application of physicochemical property analyses to successfully reduce in vivo metabolic clearance, minimize transporter-mediated biliary elimination while maintaining acceptable aqueous solubility. Compound 109 affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer.

PYRIDYL PIPERIDINES

The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.

NEW PYRIDINE ANALOGUES

The present invention relates to certain new pyridin analogues of Formula (I) Chemical formula should be inserted here. Please see paper copy Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.